<DOC>
	<DOCNO>NCT02926859</DOCNO>
	<brief_summary>Current antipsychotic treatment schizophrenia partially effective , use often associate serious side effect . Cannabidiol natural counterpart psychoactive component marijuana , delta-9- tetrahydrocannabinol psychotomimetic addictive property . In controlled clinical trial cannabidiol versus amisulpride acute paranoid schizophrenia show statistically significant clinical improvement symptom cluster schizophrenia compare baseline either treatment . Cannabidiol display significantly superior side-effect profile particular regard prolactin elevation , extrapyramidal symptom weight gain . The favorable side-effect profile potentially novel mechanism action identify molecule potential antipsychotic . However , long-term safety efficacy data still lack . This study evaluate efficacy safety novel compound cannabidiol maintenance treatment schizophrenia comparison placebo add-on establish treatment either quetiapine amisulpride , 12-months , double-blind , parallel-group , randomize , placebo-controlled clinical trial . Thereby , relevant data cannabidiol 's antipsychotic potential gain .</brief_summary>
	<brief_title>Enhancing Recovery Early Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<mesh_term>Sultopride</mesh_term>
	<mesh_term>Sulpiride</mesh_term>
	<criteria>Informed consent give subject DSMIVTR diagnosis schizophrenic psychosis ( 295.1030 , 295.90 ) patient must within first five year illness , i.e . first diagnosis schizophrenia old four year Patients must receive stable dose quetiapine amisulpride ( TAU : treatment usual ) least 6 week prior inclusion study ensure maximal effect previous medication receive . Initial PANSS total score â‰¤ 75 baseline . proper contraception female patient childbearing potential body mass index 18 40 . Lack accountability positive urine drugscreening illicit drug screen ( except cannabinoids benzodiazepine ) serious suicidal risk screen visit relevant interference axis 1 accord diagnostic evaluation ( MINI ) include residual form schizophrenia . relevant neurological medical disorder pregnancy lactation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>